Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Boule Diagnostics: A new round of boule(s) with lower costs - ABG

Boule Diagnostics

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
Beat on adj. EBIT but lower OCF
Adj. EBIT up 8.9-9.8% for '25e-'26e
Trading at 5.6x '25e EV/EBIT


Higher volume but lower ASP

Boule Diagnostics ended the year with sales of SEK 143.2m (+2% vs. ABGSCe 140.6m), organic growth of -1.8% (ABGSCe -4.3%), a gross margin of 44.6% (ABGSCe 47.1%) and improved opex. Excluding one-off restructuring charges, the gross margin in Q4 was 45.9%. While the ASP was lower than expected (SEK 35.8k vs. ABGSCe 42.5k), the number of instruments sold was higher (1,144 vs. ABGSCe 780), resulting in a small beat on sales. Management's recent focus on improving opex is starting to bear fruit, with opex 7% below our expectations. Operating cash flow improved sequentially in Q4 to SEK 15.1m (SEK 5.2m in Q3'24), but with total capex in Q4 of SEK 22.8m (SEK 20.8m in R&D capitalisation), FCF continues to be held back. As of 31 December, the company had SEK 22.7m in cash and an additional SEK 34.8m in credit facilities.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.